Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN10018 Mono or Combo with Docetaxel in Advanced Gastric/GEJ Cancer
NCT05327231Phase 1Completed
- Sponsor
- InxMed
- Start
- Jul 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ifebemtinib in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by InxMed. Primary endpoints: Safety and tolerability in combination group up to 24 months, Dose Limiting Toxicities in combination group at 21 days and 1 more. Started Jul 2020; status: completed.
02
Drugs
ifebemtinib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05327231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05327231.